Pfizer Inc. (NYSE:PFE) Shares Sold by Howe & Rusling Inc.

Howe & Rusling Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 24.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,455 shares of the biopharmaceutical company’s stock after selling 8,477 shares during the quarter. Howe & Rusling Inc.’s holdings in Pfizer were worth $702,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. AssuredPartners Investment Advisors LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $1,081,000. NEOS Investment Management LLC increased its stake in shares of Pfizer by 31.8% in the fourth quarter. NEOS Investment Management LLC now owns 350,036 shares of the biopharmaceutical company’s stock worth $9,286,000 after buying an additional 84,536 shares during the last quarter. Amica Mutual Insurance Co. raised its holdings in Pfizer by 44.7% in the fourth quarter. Amica Mutual Insurance Co. now owns 157,064 shares of the biopharmaceutical company’s stock valued at $4,167,000 after acquiring an additional 48,541 shares in the last quarter. UniSuper Management Pty Ltd boosted its stake in Pfizer by 34.8% during the 4th quarter. UniSuper Management Pty Ltd now owns 349,745 shares of the biopharmaceutical company’s stock valued at $9,279,000 after acquiring an additional 90,289 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Pfizer by 8.1% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 9,013,007 shares of the biopharmaceutical company’s stock worth $239,656,000 after acquiring an additional 674,556 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on PFE shares. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

NYSE PFE opened at $25.05 on Friday. The company has a 50-day moving average price of $26.09 and a two-hundred day moving average price of $26.97. The stock has a market cap of $142.08 billion, a price-to-earnings ratio of 17.77, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the firm earned $0.10 EPS. The firm’s revenue was up 24.7% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.